HPV – schiţă a stilului său de viaţă

Natural evolution of Papillomaviridae

Research suggests that the contemporary types of pa­pil­lo­ma­vi­ruses evolved from ancestral variants which colonized the skin of the first reptiles around 350 million years ago. Through a continuous process of adaptation, nowadays pa­pil­lomaviruses are found on the epithelial surface of a large number of species, including humans. These viruses have a high species specificity and, like humans, mammals have their own papillomaviruses⁽¹⁾ (Figure 1).
 

Initially, Papillomavirus and Polyomavirus genera were part of the Papovaviridae family that later was divided into two distinct families based on genome struc­tural differences. Despite both genera are non-en­veloped DNA viruses with oncogenic properties, they are distinct in term of genome size, organization and sequence⁽³⁾.

Papillomaviridae family contains more than 150 types of viruses with human tropism – human papillomavirus (HPV). In most cases, HPV can be considered as a com­mensal due to the evidence of HPV DNA positivity on the skin of healthy individuals⁽¹⁾.

Clinical aspects of HPV infections:
history and present

It seems that our ancestors were also preoccupied about HPV-induced lesions. Ever since Hippocrates’s time, this pathology was described based on the similarities between the visual appearance of lesions and other elements found in nature.

Therefore, mymercia was the term used for plantar warts because of its resemblance with an ant nest; thymion was the name given for anogenital warts which resemble with thyme leaves, or ficus due to its resemblance with the core of a fig. Acrochordon was the name given to common warts because they appear on the extremities and resemble a string. The current term used for anogenital warts, condyloma acuminatum, was used since ancient times and it was associated with promiscuity⁽⁴⁾ (Figure 2).
 

The majority of HPV types cause benign and self-limiting lesions of the epithelial tissue. Common warts, plantar warts, flat warts, filiform warts and pigmented warts are frequently seen in children and young people, HPV 1, HPV 2, HPV 4, HPV 27 and HPV 57 being the most common strains involved. Compared to healthy people, where spontaneous resolution is commonly seen, in immunosuppressed patients, the HPV lesions often do not resolve without treatment and recurrences are frequently seen⁽¹⁾.

Condyloma acuminatum is the most common sexually transmitted infectious disease, HPV 6 and HPV 11 being responsible for the majority of cases. These strains have a low oncogenic risk, producing benign lesions in the vast majority of cases. The issues arise from the fact that these lesions are difficult to treat and these HPV types can be vertically transmitted during delivery, leading to recurrent respiratory papillomatosis (RRP) in newborns. RRP is a debilitating disease which can lead to airways obstruction, surgical excision being the only treatment option. However, this disease tends to relapse or extend to lower respiratory and digestive tracts, with the possibility of progression to carcinoma^(1,5) (Figure 3).

Focal epithelial hyperplasia and epidermoid cysts are other types of HPV-related lesions caused by HPV 13 and 32 and by HPV 57 and 60, respectively⁽¹⁾ (Figure 4 and 5).
 

HPV structure and classification

In terms of structure, HPV is a small DNA non-enveloped virus. The genome is shielded by an icosahedral capsid composed of 72 capsomeres, and encodes three regions: “early”, “late” and “long control region”. The early region comprises six genes (E1, E2, E4, E5, E6 and E7) which encode proteins with roles in: viral replication, re­lease of new mature virions, structural changes of the keratinocyte with the apparition of the koilocyte (the hallmark of HPV infection), and eventually cell im­mor­ta­li­zation, with the possibility of malignization. E6 and E7 are the two major proteins which confer HPV car­ci­no­genic properties. The late region is composed by two genes (L1 and L2) which encode the capsid proteins with roles in viral assembly and cell entry. Late proteins have also immunogenic properties. The long control re­gion has a role in regulation of viral replication⁽⁹⁾ (Figure 6).

HPVs are classified in five genera: Alpha (a), Beta (b), Gamma (g), Miu (µ) and Niu (n) – Figure 7.
 

Alpha papillomavirus is by far the most important genera because it includes strains with high oncogenic risk. HPV 16 and HPV 18 are known as the main etio­lo­­gi­cal factors of cervical carcinomas, also having an im­por­tant role in the etiopathogenesis of other ano­ge­ni­tal malignancies, such as anal, vulvar, vaginal and penile cancers⁽¹⁾.

In recent years, it has been proven that HPV also plays a crucial role in head and neck carcinomas, HPV 16 and 18 being the most involved. Interestingly, HPV 6 and 11, which are considered low-risk oncogenic types, com­monly causing benign anogenital lesions, have also been detected in patients with oropharyngeal non-squa^­­mous cell carcinoma. This observation reinforces the theory that even low-risk oncogenic types of HPV may give rise to malignancies. Nowadays, HPV-related oro­­pha­­ryn­geal cancers are responsible for 70% of cases, there­­fore it is now being regarded as a separate clinical en­ti­ty with increasing incidence and tendency to be­come the main HPV-related cancer^(11-13).

Some types of HPV are also considered to cause some types of skin malignancies. It seems that beta pa­pil­lo­ma­viruses are the main types found in non-me­la­no­ma skin cancer biopsy samples, followed by the Alpha genera. Beta HPV 5 and 8 are the main strains encountered in squamous cell carcinoma of patients with epidermodysplasia verruciformis, a rare autosomal re­ces­sive disease, leaving the person defenseless against the HPV infection. Bowen’s disease, a squamous cell car­ci­no­ma in situ, can progress to an invasive form and seems to be associated more frequently with alpha HPV 16^(14,15).

Gamma, Miu and Niu genera are less involved in hu­man pathology, causing in general benign lesions such as common warts⁽¹⁰⁾.
 

Pathophysiology. From infection
to malignancy

HPV is an epitheliotropic virus that infects the basal layer of the epithelium via microwounds of the skin and mucosae. At this level, HPV enters the cells through a6-integrin and syndecan-1 receptors. After binding, the virus is internalized into the cell by endocytosis. The basal layer of the epithelium is composed by stem cells which are capable of division, thus maintaining the integrity and ensuring healing in case of epithelial injuries. After cell entry, viral genome is integrated into basal cells and viral replication is maintained, but with a low number of copies. Following stem cell division, the viral genetic material is transmitted to each daughter cell which will further differentiate into keratinocytes. This process is essential for viral maturation because the for­ma­tion of mature virions, capable of producing a new in­fec­tion, is possible only in the superficial layers^(1,16,17). At this level, within the practically apoptotic cells, which are losing their mitochondria, HPV encounters an oxi­di­zing environment necessary for its assemblance⁽¹⁾. After complete maturation, these viral particles are re­leased from keratinocytes during the process of phy­sio­logic desquamation. Therefore, if these new viri­ons encounter another microwound, they will start a new cycle of infection^(16,17).

The incubation period for HPV varies widely from a few weeks to several years. In the great majority of cases, spontaneous clearance is seen before lesions occur via adaptive T-cell immune response between 6 month and 2 years, with a longer period for high-risk types of HPV^(18,19).

Persistent infection carries the risk of developing ma­lig­nancies. High-risk types of HPV have the abi­li­ty of immune evasion based on their exclusively in­tra­epi­thelial life cycle without producing cellular lysis, in­flam­mation or viraemia. HPV can also downregulate cy­to­kine release. The immunogenic viral particles are removed from the epithelial surface simultaneously with the normal process of desquamation, thus low viral levels are exposed to immune cells.  Furthermore, weak recognition of viral particles by the antigen presenting cells delays the adaptive T-cell and humoral mediated immune response⁽²⁰⁾.

The key steps for carcinogenesis are: the integration of viral DNA in the host cell genome, inhibition of tu­mor suppressors like p53 and retinoblastoma pro­tein (pRb), and the stimulation of the telomerase ac­ti­vi­ty. All these processes are mediated by E6 and E7 on­co­pro­teins, causing chromosomal abnormalities and im­mor­ta­lization of the abnormal infected cells, leading to the de­velop­ment of varying degrees of dysplasia and, finally, to neoplasia^(20,21).

Viral transmission and measures to stop it

The most common mode of transmission is by se­xu­al contact, HPV infection being one of the lea­ding se­xual­ly transmitted diseases worldwide. The ver­ti­cal trans­mis­sion during delivery is also possible through the direct contact between mother’s infected mu­co­sae and the newborn’s epithelial tissue. The pos­si­bi­lity of trans­mis­sion through direct skin contact, auto­ino­cu­la­tion between anatomic sites and fomites, has also been sus­pec­ted. Nosocomial transmission was also speculated due to the persistence of HPV DNA on gynecological in­stru­ments after disinfection. This emphasizes the ne­ces­sity of knowing which types of substances or pro­ce­dures have virucidal effect on HPV. Figure 8 shows the main substances and procedures with well-known vi­ru­ci­dal efficacy and those without any effect against HPV^(22-24).

Treatment. From Chelidonium majus
to contemporary management

It seems that the lesions induced by HPV also preoccupied our ancestors and they noticed that Chelidonium majus – or greater celandine – can lead to the resolution of common warts. They used the substance found in the stalk of the plant for topical application on the lesions. Later it was proven that the substance has antiviral, immunomodulatory and cytotoxic effects through the sanguinarine, a compound that blocks cell cycle and chelidonine which induces apoptosis through the stimulation of p53 and inhibition of telomerase activity. Nowadays, greater celandine is not approved for medical uses due to its systemic toxicity, even though there is no proof of systemic absorption after topical use. Indol-3-carbinol is another compound found in cruciferous that seems to have antiviral and antiproliferative activity^(25-27).

The current treatment options for HPV-induced be­nign lesions include topical cytotoxic and antiviral agents (po­do­phyllotoxin, cidofovir), topical immunomodulatory agents (imiquimod, sinecatechins, intra­lesional inter­feron, intralesional immunotherapy with mumps, Can­di­da and Trichophyton skin test antigens) and des­truc­tive methods (trichloroacetic acid, cryotherapy, sur­gi­cal or laser excision). Malignant lesions require sur­gi­cal procedures⁽²⁸⁾.

An important prophylactic measure is to maintain the integrity of skin and mucosae, so that HPV would not reach the basal layer, the only site where it finds the receptors needed for binding and for entering the cell. These can be achieved through maintaining our skin hydrated and by avoiding microtrauma.

Because HPV infections which lead to malignant lesions are asymptomatic and the cancers are frequently diagnosed in late stages, it is of paramount importance to get preexposure prophylaxis. Vaccination is the only way to prevent the development of HPV-induced malig­nan­cies and also offers protection against HPV types that cause condyloma acuminatum. The current approved vac­cine, Gardasil 9®, offers protection against nine of the most frequently involved strains: HPV 6, HPV 11, HPV 16, HPV 18, HPV 31, HPV 33, HPV 45, HPV 52 and HPV 58. The efficacy in preventing HPV infection is nearly 100%. The protection is achieved through a humoral im­mune response characterized by the production of neu­tra­li­zing antibodies (IgG) which confer protection for at least 10 years. The humoral immune response after na­tu­ral infection is weak, delayed and half of the patients don’t develop antibodies. Conversely, after vaccination, a robust response is seen, with faster seroconversion. This happens due to highly immunogenic virus-like pro­teins (VLPs) of the vaccine and the administration route. VLPs are purified L1 major capsid viral proteins that are highly immunogenic and have the property to self-assemble. The intramuscular administration allows a better interaction between immunogenic particles and im­mune cells.

Currently, the indication for vaccination starts at 9 years old up to 45 years old for both males and females. Between 9 and 14 years old, a two-dose regimen is considered sufficient, but over 14 years old, a three-dose regimen is necessary for providing a protective immune response. The purpose of vaccination is to decrease the incidence of anogenital and oropharyngeal malignancies induced by HPV^(29,30).

Speculative discussion

The mechanism of co-evolution between HPV and human host is complex. HPV belongs to normal skin microbiota. More than fifteen types of beta and gamma papillomaviruses seem to live on healthy human skin without causing any damage. In order to maintain an equilibrium, the human body has to develop a certain tolerance for HPV. In return, HPV has to confer some ad­van­tages. As a member of human skin microbiota (along with bacteria, archaea and other viruses), HPV con­fers protection against other bacteria, fungi or other more virulent viruses⁽³¹⁾.

Taking into account that HPV’s E6 and E7 onco­pro­teins stimulate the telomerase activity⁽²⁴⁾, we can spe­cu­late that HPV may act like an antiaging com­pound through preventing apoptosis. This could be ano­ther advantage conferred by HPV, in the absence of ma­lig­ni­zation. In this regard, it is interesting that the repli­ca­tion cycle of HPV is blocked in less differentiated neo­plas­tic cells. Therefore, we assume that the initiation of car­ci­no­genesis is not beneficial for HPVs.

Conclusions

Papillomaviridae is a large family of small DNA viru­ses with ancient origins. They are found on the skin and mu­co­sae of many species, including humans, and are cha­rac­te­rized by high species specificity, each verte­brate having its own type of papillomavirus.

In the majority of cases, it can be considered as a com­mensal (with unclear advantages for the host). Most in­fec­tions are clinically unapparent, with viral clea­rance pro­du­ced via cellular mediated im­mu­­nity, but the per­sis­tence of HPV can give rise to ma­lig­nan­cies.

Vaccination is the only way to decrease the incidence of HPV-induced cancers and should be indicated before natural infection occurs.